Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers

ANCREN AZ, Virginie, et al.

Abstract
The new anti-aggregating agent prasugrel is bioactivated by cytochromes P450 (CYP) 3A and 2B6. Ritonavir is a potent CYP3A inhibitor and was shown in vitro as a CYP2B6 inhibitor. The aim of this open-label cross-over study was to assess the effect of ritonavir on prasugrel active metabolite (prasugrel AM) pharmacokinetics in healthy volunteers. Ten healthy male volunteers received 10 mg prasugrel. After at least a week washout, they received 100 mg ritonavir, followed by 10 mg prasugrel 2 hr later. We used dried blood spot sampling method to monitor prasugrel AM pharmacokinetics (C(max), t(1/2), t(max), AUC(0-6 hr)) at 0, 0.25, 0.5, 1, 1.5, 2, 4 and 6 hr after prasugrel administration. A 'cocktail' approach was used to measure CYP2B6, 2C9, 2C19 and 3A activities. In the presence of ritonavir, prasugrel AM C(max) and AUC were decreased by 45% (mean ratio: 0.55, CI 90%: 0.40-0.7, p = 0.007) and 38% (mean ratio: 0.62, CI 90%: 0.54-0.7, p = 0.005), respectively, while t(1/2) and t(max) were not affected. Midazolam metabolic ratio (MR) dramatically decreased in presence of ritonavir (6.7 ± 2.6 versus [...]

Reference

DOI: 10.1111/j.1742-7843.2012.00932.x
PMID: 22900583
Pharmacokinetic Interaction Between Prasugrel and Ritonavir in Healthy Volunteers

Virginie Ancrenaz1, Julien Déglon2, Caroline Samer1,3, Christian Staub2, Pierre Dayer1,2, Youssef Daali1,3 and Jules Desmeules1,3

1Clinical Pharmacology and Toxicology Service, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland, 2Unit of Toxicology, University Center of Legal Medicine, Geneva, Switzerland, and 3Swiss Center of Applied Human Toxicology, Geneva University, Geneva, Switzerland

(Received 7 May 2012; Accepted 9 August 2012)

Abstract: The new anti-aggregating agent prasugrel is bioactivated by cytochromes P450 (CYP) 3A and 2B6. Ritonavir is a potent CYP3A inhibitor and was shown in vitro as a CYP2B6 inhibitor. The aim of this open-label cross-over study was to assess the effect of ritonavir on prasugrel active metabolite (prasugrel AM) pharmacokinetics in healthy volunteers. Ten healthy male volunteers received 10 mg prasugrel. After at least a week washout, they received 100 mg ritonavir, followed by 10 mg prasugrel 2 h later. We used dried blood spot sampling method to monitor prasugrel AM pharmacokinetics (Cmax, t1/2, tmax, AUC0–t, AUC0–∞) at 0, 0.25, 0.5, 1, 1.5, 2, 4 and 6 h after prasugrel administration. A 'cocktail' approach was used to measure CYP2B6, 2C9, 2C19 and 3A activities. In the presence of ritonavir, prasugrel AM Cmax and AUC were decreased by 45% (mean ratio: 0.55, CI 90%: 0.40–0.7, p = 0.007) and 38% (mean ratio: 0.62, CI 90%: 0.54–0.7, p = 0.005), respectively, while t1/2 and tmax were not affected. Midazolam metabolic ratio (MR) dramatically decreased in presence of ritonavir (6.7 ± 2.6 versus 0.13 ± 0.07) reflecting an almost complete inhibition of CYP3A4, whereas omeprazole, flurbiprofen and bupropion MR were not affected. These data demonstrate that ritonavir is able to block prasugrel CYP3A4 bioactivation. This CYP-mediated drug–drug interaction might lead to a significant reduction of prasugrel efficacy in HIV-infected patients with acute coronary syndrome.

Introduction

Prasugrel is a recently commercialized thienopyridine antiplatelet agent used to prevent atherothrombotic events in patients with acute coronary syndrome who are undergoing percutaneous coronary intervention [1].

The active metabolite of prasugrel (prasugrel AM) is an irreversible inhibitor of ADP-P2Y12 platelet receptors, explaining the anti-aggregating effect of prasugrel. This pro-drug is rapidly hydrolysed by carboxylesterases into a thiolactone intermediate metabolite that is transformed by cytochromes P450 (CYP) into its pharmacologically active metabolite (fig. 1). CYP3A and CYP2B6 are primarily responsible for this transformation while CYP2C19 and CYP2C9 are involved to a lesser extent [2]. CYP3A and 2B6 represent, respectively, 40% and 5% of the total cytochromes in the human liver and they are known to be involved in the oxidative metabolism of a wide range of drugs in clinical use [3,4]. Consequently, in vivo interactions between prasugrel and other drugs affecting these CYPs are possible. The effects of some CYP inhibitors or inducers on prasugrel bioactivation have been assessed previously. For example, there was no change in prasugrel AM formation or the inhibition of platelet aggregation when prasugrel was administered with ketoconazole (a CYP3A inhibitor), atorvastatin (a CYP3A substrate) or rifampicin (a CYP3A inducer) [5–7]. These studies suggest that the production of prasugrel AM is not altered by induction or inhibition of CYP3A. However, an in vitro study showed that prasugrel was mainly metabolized by CYP3A and CYP2B6 and simultaneous inhibition of these two pathways significantly decreased prasugrel bioactivation. Indeed, ritonavir was a potent inhibitor of prasugrel bioactivation in human liver microsomes, raising the possibility of a pharmacokinetic drug–drug interaction between ritonavir and prasugrel in vivo [8]. Such an interaction could reduce the efficacy of prasugrel. In vivo experiments are lacking to confirm these in vitro data in human beings.

Ritonavir is an antiretroviral agent widely used as a pharmacokinetic booster in patients with HIV infection to increase the plasma concentrations of other antiretroviral drugs. In HIV patients with acute coronary syndrome, these two drugs could be largely prescribed concomitantly. Indeed, ritonavir is known to be a potent inhibitor of CYP3A and CYP2B6 and is a weaker inhibitor of CYP2C9 [8–12].

While blood volume is seldom a major limitation of clinical trials, the invasiveness of phlebotomy certainly is. Compared with classic venipuncture, dried blood spots (DBS) sampling is less invasive and can be easily performed. Additionally, when shipping and storing samples, DBS sampling eliminates the need for dry ice, plasma separation and addition of anticoagulants that are required to maintain the viability of traditional blood samples. Regarding these benefits, DBS sampling has grown in popularity in the clinical and the pharmaceutical communities over the past decade. Recent publications demonstrated that DBS is a viable approach for the quantitative
This open-label cross-over study was conducted in 10 healthy volunteers at the clinical research unit of the Geneva University Hospitals. The study was designed to assess the potential pharmacokinetic interaction between ritonavir and prasugrel in healthy volunteers. The activities of the CYPs involved in prasugrel metabolism were also evaluated using a cocktail approach.

Material and Methods

Volunteers. Inclusion criteria required that volunteers be healthy males between 18 and 60 years of age, have a body mass index between 18 and 25 kg/m², and be able to understand and read the French language. Candidates were ineligible if they were smokers; used any drug or food such as grapefruit in the month prior to the study; were hypersensitive to prasugrel, ritonavir or constituents of the tablets; consumed alcohol regularly; had concomitant disease; or used any drug or food such as grapefruit in the month prior to the study. Volunteers who used drugs associated with an increased risk of bleeding in the 10 days preceding the start of the study were excluded, as were those with a familial history of clotting disorders, antecedent of haemorrhagic disease, a previous or active gastrointestinal ulcer. University Hospitals. This study was conducted in accordance with Good Clinical Practice Guidelines and the Declaration of Helsinki.

Study design. This open-label cross-over study was conducted in 10 healthy volunteers at the clinical research unit of the Geneva University Hospitals. The study was designed to assess the potential pharmacokinetic interaction between ritonavir and prasugrel in healthy volunteers. The activities of the CYPs involved in prasugrel metabolism were also evaluated using a cocktail approach.

Analysis of DBS samples. Capillary blood samples for pharmacokinetic analysis were collected prior to and 0.25, 0.5, 1, 1.5, 2, 3, 4 and 6 hr after the administration of a single dose of prasugrel. After a small finger prick using disposable lancet (BD Microtainer: Contact-Activated Lancet, United Kingdom), 5 μl blood was spotted onto filter paper (Protein Saver 903 Card, Whatman) that had been previously soaked with 20 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mM. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mA. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mA. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mA. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mA. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mA. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mA. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mA. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mA. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mA. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'-methylacetophenone (BMAP) at 30 mA. This pre-treatment allows the unstable thiol group to be derivatized. After 30 min, 5 μl of 2-bromo-3'
Multiple reactions monitoring parameters for the detection of prasugrel, prasugrel active metabolite, prasugrel active metabolite-d3, midazolam, omeprazole, bupropion and flurbiprofen.

<table>
<thead>
<tr>
<th>Compounds</th>
<th>Polarity</th>
<th>Q1→Q3 (m/z)</th>
<th>CE (V)</th>
<th>DP (V)</th>
<th>Dwell time (ms)</th>
<th>LLQ (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prasugrel</td>
<td>+</td>
<td>374→206</td>
<td>23</td>
<td>100</td>
<td>2</td>
<td>0.5</td>
</tr>
<tr>
<td>Prasugrel AM¹</td>
<td>+</td>
<td>498→348</td>
<td>28</td>
<td>100</td>
<td>2</td>
<td>0.5</td>
</tr>
<tr>
<td>Prasugrel AM-d3¹</td>
<td>+</td>
<td>501→348</td>
<td>25</td>
<td>150</td>
<td>2</td>
<td>0.5</td>
</tr>
<tr>
<td>Midazolam</td>
<td>+</td>
<td>326→291</td>
<td>37</td>
<td>165</td>
<td>2</td>
<td>0.1</td>
</tr>
<tr>
<td>Omeprazole</td>
<td>+</td>
<td>346→198</td>
<td>19</td>
<td>66</td>
<td>2</td>
<td>0.5</td>
</tr>
<tr>
<td>Bupropion</td>
<td>+</td>
<td>240→131</td>
<td>30</td>
<td>80</td>
<td>2</td>
<td>0.5</td>
</tr>
<tr>
<td>Flurbiprofen</td>
<td>+</td>
<td>243→199</td>
<td>18</td>
<td>50</td>
<td>2</td>
<td>100</td>
</tr>
</tbody>
</table>

CE, collision energy; DP, declustering potential; LLQ, lower limit of quantification.
¹Compounds derivatized with 2-bromo-3-methoxyacetophenone (BMAP).

**Results**

**Volunteers.**

Ten healthy male volunteers were enrolled in the study. Volunteers were between 21 and 41 years of age with a mean (±S.D.) of 26 ± 6 years. Volunteers ranged in height from 165 to 185 cm, weighed between 63 and 95 kg and had a mean body mass index (±S.D.) of 22.8 ± 2 kg/m². They were in good health, as determined by review of their medical history and physical examination. All 10 volunteers successfully completed the study. No adverse effects were reported during the study and all volunteers were included in the pharmacokinetic analysis. One volunteer was excluded from the evaluation of CYP2C19 activity because omeprazole and its metabolite were not detectable in his plasma and DBS.

**Prasugrel pharmacokinetics.**

In comparison with prasugrel alone, AUC₀–₆ hr and Cₘₚₐₓ decreased by 38.4% (mean ratio: 0.62, CI 90%: 0.54; 0.7, p = 0.005) and 44.9% (mean ratio: 0.55, CI 90%: 0.4; 0.7, p = 0.007), respectively, when ritonavir was administered with prasugrel. However, ritonavir did not affect the time to reach maximum concentration (tₘₚₐₓ; median ratio: 1, CI 90%: 0.5; 2, p = 0.73) and half-life (t₁/₂; mean ratio: 0.94, CI 90%: 0.66; 1.22, p = 0.33) of prasugrel AM (figs 2 and 3; table 2).

**Cytochrome P450 activities.**

Midazolam MR was 97.8 ± 1.4% lower after ritonavir administration compared with the values for prasugrel alone (mean ratio: 0.022, CI 90%: 0.014; 0.03, p = 0.005). When ritonavir was co-administered with prasugrel, midazolam AUC₀–₆ hr and Cₘₚₐₓ were 26 times and 6 times, respectively, the values obtained for prasugrel alone. Omeprazole MR (mean ratio: 0.92, CI 90%: 0.49; 1.35, p = 0.59), AUC₀–₆ hr (mean ratio: 1.25, CI 90%: 0.94; 1.57, p = 0.44) and Cₘₚₐₓ (mean ratio: 1.54, CI 90%: 0.77; 2.32, p = 0.44) were not affected by ritonavir, and neither were flurbiprofen MR (mean ratio: 1.02, CI 90%: 0.78; 1.26, p = 0.58), AUC₀–₆ hr (mean ratio: 0.95, CI 90%: 0.84; 1.05, p = 0.44) or Cₘₚₐₓ (mean ratio: 0.98, CI 90%: 0.82; 1.14, p = 0.72). Unexpectedly,

© 2012 The Authors
As determined from a previous in vitro study, 38–70% of the bioactivation of oxo-prasugrel to prasugrel AM is performed by CYP3A4 and 2–26% is performed by CYP2B6 [2]. In the present study, ritonavir was used to investigate the effect of the inhibition of CYP3A and possibly other CYPs on the prasugrel AM pharmacokinetics.

In the present study, ritonavir totally inhibited CYP3A4/5 activity as indicated by the decrease of more than 97% of midazolam MR and the increase of midazolam’s AUC_{0–6 hr} to a level 26 times that of observed without ritonavir, and the increase of midazolam’s C_{max} to a level 6 times that observed without ritonavir. These results are in agreement with previous studies demonstrating that ritonavir is a very potent CYP3A inhibitor [11,18]. A previous study assessing the effect of ketoconazole on prasugrel pharmacokinetics and pharmacodynamics demonstrated a decrease in prasugrel AM C_{max} while AUC and platelet aggregation were not affected [5]. These contradictory results might be due to a higher CYP3A inhibition potential of ritonavir in comparison with ketoconazole [19]. In fact, ritonavir inhibited CYP3A more strongly than ketoconazole, as indicated by its increase of midazolam’s AUC by a factor 28.4 while ketoconazole increased it by a factor 10–15 [18,20,21]. The pharmacokinetic differences between the results of ketoconazole and ritonavir could be explained by the mechanism of inhibition of the CYP3A4 by these molecules: while ritonavir is a competitive and non-competitive irreversible inhibitor, ketoconazole is only a competitive reversible inhibitor of CYP3A4.

Regarding CYP2B6 activity, ritonavir did not significantly affect either bupropion or 5-hydroxybupropion pharmacokinetics. This may be explained by the high Ki (5 μM) value of CYP2B6, which is higher than the expected ritonavir C_{max} after a 100 mg dose (1–2 μM) [22]. Higher concentrations of ritonavir might therefore be necessary to highlight any CYP2B6 inhibition measured through bupropion metabolism. Furthermore, omeprazole MR, flurbiprofen MR and their pharmacokinetic parameters did not change after ritonavir treatment.

One limitation of this study was that ritonavir was administered as a single dose. Ritonavir is one of the most potent known inhibitors of CYP3A but may have an induction effect when administered long-term [23]. However, this remains controversial, because some in vivo studies have failed to demonstrate induction and instead reported persistent CYP3A inhibition, even after long-term use [24]. The data obtained in our study are consistent with a pharmacokinetic drug–drug interaction between prasugrel and ritonavir via a potent inhibition of CYP3A4/5. Pharmacodynamic measurements were not performed in this study as prasugrel was administered in single dose. Nevertheless, according to some studies, from a clinical point of view, decreases in prasugrel AM production may be associated with lower platelet inhibition [25,26].

In conclusion, the inhibition of the bioactivation pathways of prasugrel by ritonavir mainly via CYP3A4/5 significantly affected prasugrel AM pharmacokinetics. This study highlights the importance of very carefully considering drugs affecting CYPs that might be prescribed concomitantly with prasugrel. Prasugrel is metabolized mainly by the CYP3A isoform that is

**Fig. 2.** Mean (±S.D.) whole blood concentrations for prasugrel’s active metabolite in dried blood spots after prasugrel alone (Δ) or prasugrel with ritonavir (●). Values are shown as the mean ± S.D.

**Fig. 3.** Effect of ritonavir on individual (A) AUC_{0–6 hr} or (B) C_{max} of the prasugrel active metabolite after administration of 10 mg prasugrel alone or 10 mg prasugrel with 100 mg ritonavir. *p < 0.05, **p ≤ 0.005.

bupropion MR (mean ratio: 1.02, CI 90%: 0.85; 1.19, p = 0.88), AUC_{0–6 hr} (mean ratio: 1, CI 90%: 0.93; 1.1, p = 0.96) and C_{max} (mean ratio: 1.03, CI 90%: 0.85; 1.21, p = 0.96) were not influenced by the co-administration of ritonavir and prasugrel (table 3; fig. 4).

**Discussion**

This study shows that prasugrel pharmacokinetics is significantly altered by ritonavir. In fact, ritonavir significantly decreased prasugrel AM AUC_{0–6 hr} and C_{max} while t_{max} and t_{1/2} were not affected.
Fig. 4. Effect of ritonavir on individual metabolic ratios of (A) midazolam, (B) flurbiprofen, (C) omeprazole and (D) bupropion after administration of 10 mg prasugrel or 10 mg prasugrel with 100 mg ritonavir. *p < 0.05, **p ≤ 0.005.
inhibited, for example, by imatinib, ketoconazole and other antiretroviral drugs. CYP2B6, which is involved in the metabolism of prasugrel, also metabolizes other drugs such as methadone, cyclophosphamides and tramadol. Further PK/PD studies are needed to investigate the impact of these CYP-mediated drug–drug interactions on patients receiving prasugrel treatment and particularly in HIV patients with acute coronary syndrome simultaneously treated by prasugrel and ritonavir.

Acknowledgements
The authors wish to thank Jocelyne Chabert, Fabienne Doffey-Lazeyras and Mélanie Verdon for their help and assistance as well as the clinical research centre of the Geneva University Hospitals. The clinical study was supported by the division of Anesthesiology, Pharmacology and Intensive Care, Geneva University Hospitals.

References
11 Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006;42:52–60.